IHC4 Score and Its Impact on Breast Cancer Recurrence Risk - Oncology

More Info

---

The IHC4 score is a valuable tool in assessing the risk of breast cancer recurrence, particularly in hormone receptor-positive invasive breast cancer. It combines the results of immunohistochemical (IHC) tests for estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki-67, a marker of cell proliferation. The IHC4 score helps to stratify patients into different risk categories, guiding treatment decisions and follow-up strategies.

In your case, the provided pathology results indicate the following:
- Invasive Ductal Carcinoma (IDC)
- Grade 1
- pT1cN0M0 (indicating a small tumor with no lymph node involvement or distant metastasis)
- ER positive (80%)
- PR positive (50%)
- HER2 negative (score 1+)
- Ki-67 at 5%
The IHC4 score of -23.675 suggests a low risk of recurrence, which aligns with the characteristics of your tumor. Generally, a lower IHC4 score indicates a better prognosis and a lower likelihood of recurrence. However, discrepancies in the IHC4 score calculations can arise from variations in the interpretation of the IHC results or the specific formulas used to calculate the score.

It's important to note that the HER2 score of 1+ is considered negative in most clinical contexts, which means that it does not typically warrant HER2-targeted therapies like trastuzumab (Herceptin). This is crucial because HER2 positivity can significantly influence treatment options and prognosis.
If you have calculated a different IHC4 score using online tools or resources, it may be due to differences in the input values or the formulas used. For instance, the HER2 score should be entered as 0 for IHC4 calculations if it is 1+, as this indicates a lack of significant HER2 overexpression. Therefore, it is advisable to confirm the input values with your healthcare provider to ensure accuracy.

Regarding your concerns about the potential errors in the hospital's calculations or treatment plans, it is essential to have open communication with your oncologist. They can clarify the rationale behind your treatment plan based on the IHC4 score and other clinical factors. If you feel uncertain or anxious about your treatment, consider seeking a second opinion from another oncologist or a breast cancer specialist. This can provide you with additional insights and reassurance.

In summary, the IHC4 score is a critical component in evaluating breast cancer recurrence risk. Your score of -23.675 suggests a favorable prognosis, but it is essential to ensure that all data inputs are accurate and consistent. Open dialogue with your healthcare team will help address any concerns and guide your treatment decisions moving forward. Remember, breast cancer treatment is highly individualized, and your medical team is best equipped to tailor a plan that suits your specific situation.